Company TMS Co., Ltd.

Equities

4891

JP3544960002

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 07:00:00 22/05/2024 BST			5-day change	1st Jan Change
234 ^JPY	-2.09%		-3.31%	+24.47%

05-20	Tennant Minerals Produces 'High-Grade' Concentrates from Bluebird Discovery Samples	MT
05-14	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	MT

TMS Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and marketing of pharmaceuticals. The Company conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.

Number of employees: 14

Managers	Title	Age	Since
Keiji Hasumi FOU	Founder	66	16/02/05
Takuro Wakabayashi PSD	President	57	30/04/11
Go Ito ADM	Chief Administrative Officer	54	31/01/18
Noriaki Inamura CTO	Chief Tech/Sci/R&D Officer	68	30/11/20
Kazuo Honda AUD	Comptroller/Controller/Auditor	74	31/03/15

Members of the board	Title	Age	Since
Takuro Wakabayashi PSD	President	57	30/04/11
Reiko Namikawa BRD	Director/Board Member	70	30/04/21
Ken Takanashi BRD	Director/Board Member	60	29/02/20
Noriaki Inamura CTO	Chief Tech/Sci/R&D Officer	68	30/11/20
Keiji Hasumi FOU	Founder	66	16/02/05
Kazuo Honda AUD	Comptroller/Controller/Auditor	74	31/03/15
Go Ito ADM	Chief Administrative Officer	54	31/01/18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	40,304,367	35,981,037 ( 89.27 %)	10 ( 0.000025 %)	89.27 %

Name	Equities	%	Valuation
DCI Partners KK 10.19 %	4,107,920	10.19 %	6 M ¥
Mitsubishi UFJ Capital Co., Ltd. 9.124 %	3,677,420	9.124 %	6 M ¥
RTW Investments LP 8.954 %	3,608,716	8.954 %	6 M ¥
Nissay Capital Co., Ltd. 7.291 %	2,938,640	7.291 %	5 M ¥
TOHOKU University Venture Partners Co., Ltd. 7.061 %	2,845,960	7.061 %	4 M ¥
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 3.556 %	1,433,320	3.556 %	2 M ¥
Xseed Partners LLP 3.548 %	1,430,000	3.548 %	2 M ¥
Mitsui Sumitomo Insurance Venture Capital Co. Ltd. 2.648 %	1,067,200	2.648 %	2 M ¥
Okasan Capital Partners, Inc. 2.374 %	956,900	2.374 %	1 M ¥
Keiji Hasumi 1.995 %	804,000	1.995 %	1 M ¥

TMS Co., Ltd.

Keio Fuchu 1-chome Building, 11/F 1-9 Fuchu-cho

183-0055, Tokyo

http://www.tms-japan.co.jp/ja/index.html

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

239 JPY

Average target price

760 JPY

Spread / Average Target

+217.99%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
TMS CO., LTD.	+24.47%	61.7M
MODERNA, INC.	+44.48%	55.07B
LONZA GROUP AG	+43.57%	40.22B
IQVIA HOLDINGS INC.	-0.86%	41.79B
CELLTRION, INC.	-7.59%	28.17B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.28B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	18.93B
BIO-TECHNE CORPORATION	+7.15%	13.03B
MEDPACE HOLDINGS, INC.	+29.40%	12.26B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.21B

Other Biotechnology & Medical Research